Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 230

Related Articles by Review for PubMed (Select 20614454)

1.

Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.

Stowe R, Ives N, Clarke CE, Deane K; van Hilten, Wheatley K, Gray R, Handley K, Furmston A.

Cochrane Database Syst Rev. 2010 Jul 7;(7):CD007166. doi: 10.1002/14651858.CD007166.pub2. Review.

PMID:
20614454
2.

Dopamine agonist therapy in early Parkinson's disease.

Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ, Shah L, Wheatley K, Gray R.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006564. doi: 10.1002/14651858.CD006564.pub2. Review.

PMID:
18425954
3.

Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease.

Stowe R, Ives N, Clarke CE, Handley K, Furmston A, Deane K, van Hilten JJ, Wheatley K, Gray R.

Mov Disord. 2011 Mar;26(4):587-98. doi: 10.1002/mds.23517. Epub 2011 Mar 2. Review.

PMID:
21370258
4.

Ropinirole for levodopa-induced complications in Parkinson's disease.

Clarke CE, Deane KH.

Cochrane Database Syst Rev. 2001;(1):CD001516. Review.

PMID:
11279718
5.

Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.

Deane KH, Spieker S, Clarke CE.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004553. Review.

PMID:
15495118
6.

Ropinirole for levodopa-induced complications in Parkinson's disease.

Clarke CE, Deane KH.

Cochrane Database Syst Rev. 2000;(3):CD001516. Review. Update in: Cochrane Database Syst Rev. 2001;(1):CD001516.

PMID:
10908503
7.

Monoamine oxidase B inhibitors for early Parkinson's disease.

Macleod AD, Counsell CE, Ives N, Stowe R.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004898. Review.

PMID:
16034956
8.

Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.

Caslake R, Macleod A, Ives N, Stowe R, Counsell C.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006661. doi: 10.1002/14651858.CD006661.pub2. Review.

PMID:
19821381
9.

Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease.

Clarke CE, Deane KD.

Cochrane Database Syst Rev. 2001;(1):CD001519. Review.

PMID:
11279721
10.

Cabergoline for levodopa-induced complications in Parkinson's disease.

Clarke CE, Deane KH.

Cochrane Database Syst Rev. 2001;(1):CD001518. Review.

PMID:
11279720
11.

Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease.

Clarke C E, Speller J M, Clarke J A.

Cochrane Database Syst Rev. 2000;(3):CD002259. Review.

PMID:
10908539
12.

Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.

Clarke CE, Deane KH.

Cochrane Database Syst Rev. 2001;(1):CD001517. Review.

PMID:
11279719
13.

Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.

Clarke CE, Deane KH.

Cochrane Database Syst Rev. 2000;(3):CD001517. Review. Update in: Cochrane Database Syst Rev. 2001;(1):CD001517.

PMID:
10908504
14.

Pramipexole for levodopa-induced complications in Parkinson's disease.

Clarke C E, Speller J M, Clarke J A.

Cochrane Database Syst Rev. 2000;(3):CD002261. Review.

PMID:
10908540
15.

Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.

Deane KH, Spieker S, Clarke CE.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004554. Review.

PMID:
15495119
16.

Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.

Kulisevsky J, Pagonabarraga J.

Drug Saf. 2010 Feb 1;33(2):147-61. doi: 10.2165/11319860-000000000-00000. Review.

PMID:
20082541
17.

Bromocriptine versus levodopa in early Parkinson's disease.

Ramaker C, van Hilten JJ.

Cochrane Database Syst Rev. 2000;(3):CD002258. Review. Update in: Cochrane Database Syst Rev. 2007;(4):CD002258.

PMID:
10908538
18.

Physiotherapy versus placebo or no intervention in Parkinson's disease.

Tomlinson CL, Patel S, Meek C, Clarke CE, Stowe R, Shah L, Sackley CM, Deane KH, Herd CP, Wheatley K, Ives N.

Cochrane Database Syst Rev. 2012 Jul 11;7:CD002817. doi: 10.1002/14651858.CD002817.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;8:CD002817.

PMID:
22786482
19.

Physiotherapy versus placebo or no intervention in Parkinson's disease.

Tomlinson CL, Patel S, Meek C, Herd CP, Clarke CE, Stowe R, Shah L, Sackley CM, Deane KH, Wheatley K, Ives N.

Cochrane Database Syst Rev. 2013 Sep 10;9:CD002817. doi: 10.1002/14651858.CD002817.pub4. Review.

PMID:
24018704
20.

Off spells and dyskinesias: pharmacologic management of motor complications.

Khan TS.

Cleve Clin J Med. 2012 Jul;79 Suppl 2:S8-13. doi: 10.3949/ccjm.79.s2a.02. Review.

PMID:
22761271
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk